Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...

Introduction: Infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) is a public health problem ...

The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

Dynavax is kicking off May’s Hepatitis Awareness Month with a new push to improve education around hepatitis B and the ...

There's a vaccine for hepatitis B that, according to the CDC, can help to prevent millions of deaths worldwide.

A pioneering study uncovers crucial immune dynamics in hepatitis B, offering new insights into how immune responses evolve ...

Chronic HBV was associated with increased risk for adverse COVID-19 outcomes, but the risk was lower among coinfected patients vaccinated against COVID-19.

The session titled “Defeating Cancer by Curing Infections” at European Society of Clinical Microbiology and Infectious ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical outcomes of ...

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver ...

Although progress has been made towards the Sustainable Development Goal (SDG) target 3.3 to end the epidemics of HIV, tuberculosis (TB), and combatting viral hepatitis B and C and sexually ...